pubmed.ncbi.nlm.nih.gov

Cisplatin-Induced Ototoxicity: Effects, Mechanisms and Protection Strategies - PubMed

  • ️Thu Jan 01 2015

Review

Cisplatin-Induced Ototoxicity: Effects, Mechanisms and Protection Strategies

Angela Callejo et al. Toxics. 2015.

Abstract

Cisplatin is a highly effective chemotherapeutic agent that is widely used to treat solid organ malignancies. However, serious side effects have been associated with its use, such as bilateral, progressive, irreversible, dose-dependent neurosensory hearing loss. Current evidence indicates that cisplatin triggers the production of reactive oxygen species in target tissues in the inner ear. A variety of agents that protect against cisplatin-induced ototoxicity have been successfully tested in cell culture and animal models. However, many of them interfere with the therapeutic effect of cisplatin, and therefore are not suitable for systemic administration in clinical practice. Consequently, local administration strategies, namely intratympanic administration, have been developed to achieve otoprotection, without reducing the antitumoral effect of cisplatin. While a considerable amount of pre-clinical information is available, clinical data on treatments to prevent cisplatin ototoxicity are only just beginning to appear. This review summarizes clinical and experimental studies of cisplatin ototoxicity, and focuses on understanding its toxicity mechanisms, clinical repercussions and prevention strategies.

Keywords: cisplatin; hearing loss; intratympanic; ototoxicity; protective treatment.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Similar articles

Cited by

References

    1. Rybak L.P., Whitworth C.A., Mukherjea D., Ramkumar V. Mechansims of cisplatin-induced ototoxicity and prevention. Hear Res. 2007;226:157–167. doi: 10.1016/j.heares.2006.09.015. - DOI - PubMed
    1. Rybak L.P., Mukherjea D., Jajoo S., Ramkumar V. Cisplatin ototoxicity and protection: clinical and experimental studies. Tohoku J. Exp. Med. 2009;219:177–186. doi: 10.1620/tjem.219.177. - DOI - PMC - PubMed
    1. Hill G.W., Morest D.K., Parham K. Cisplatin-Induced ototoxicity: Effect of intatympanic dexamethasone injections. Otol. Neurotol. 2008;29:1005–1011. doi: 10.1097/MAO.0b013e31818599d5. - DOI - PMC - PubMed
    1. Wang D., Lippard S.J. Cellular processing of platinum anticancer drugs. Nat. Rev. Drug Discov. 2005;4:307–320. doi: 10.1038/nrd1691. - DOI - PubMed
    1. Rybak L. Mechanisms of cisplatin ototoxicity and progress in otoprotection. Curr. Opin. Otolaryngol. Head Neck Surg. 2007;15:364–369. doi: 10.1097/MOO.0b013e3282eee452. - DOI - PubMed

Publication types